NS-089/NCNP-02

DRUG3 trials

Sponsors

National Center of Neurology and Psychiatry, Japan, Nippon Shinyaku Co., Ltd., NS Pharma, Inc.

Conditions

DMDDuchenne Muscular DystrophyDuchenne Muscular Dystrophy (DMD)Exon 44

Phase 1

Exploratory Study of NS-089/NCNP-02 in DMD

CompletedNCT04129294

National Center of Neurology and Psychiatry, JapanDuchenne Muscular Dystrophy

Start: 2019-12-02End: 2022-05-31Updated: 2022-09-29

Phase 2

Extension Study of NS-089/NCNP-02 in DMD

Active, not recruitingNCT05135663

Nippon Shinyaku Co., Ltd.Duchenne Muscular Dystrophy (DMD)

Start: 2021-06-23End: 2027-04-30Updated: 2025-07-20

NS-089/NCNP-02-201 in Boys With Duchenne Muscular Dystrophy (DMD)

Active, not recruitingNCT05996003

NS Pharma, Inc.DMD, Duchenne Muscular Dystrophy, Exon 44

Start: 2024-02-22End: 2027-02-26Target: 20Updated: 2026-09-15

Related Papers

Phase 1/2 trial of brogidirsen: Dual-targeting antisense oligonucleotides for exon 44 skipping in Duchenne muscular dystrophy.

2025-01-0910 citations